Drugs / Nocardia Rubra Cell Wall Skeleton
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05533892 | Sep 2022 → Aug 2024 | hepatocellular carcinoma | Wan-Guang Zhang | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06356714 | Mar 2025 → Sep 2026 expected | colorectal cancer | Sun Jing | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05368142 | May 2022 → Jun 2023 | ulcer of lower limbs | The Affiliated Hospital of Xuzhou Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nocardia rubra cell wall skeleton | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05533892 ↗ |
| Route | Topical | “Nocardia rubra cell wall skeleton for external application” NCT05368142 ↗ |